APA (7th ed.) Citation

Yan, Z., Yang, K., Tang, X., Bi, Y., Ding, Y., Deng, M., . . . Chen, T. (2022). Norcantharidin Nanostructured Lipid Carrier (NCTD-NLC) Suppresses the Viability of Human Hepatocellular Carcinoma HepG2 Cells and Accelerates the Apoptosis. Journal of Immunology Research, 2022, 1-10. https://doi.org/10.1155/2022/3851604

Chicago Style (17th ed.) Citation

Yan, Zijun, Kun Yang, Xiang Tang, Yunfeng Bi, Yuzhen Ding, Mengyue Deng, Die Xia, Yunqi Zhao, and Tong Chen. "Norcantharidin Nanostructured Lipid Carrier (NCTD-NLC) Suppresses the Viability of Human Hepatocellular Carcinoma HepG2 Cells and Accelerates the Apoptosis." Journal of Immunology Research 2022 (2022): 1-10. https://doi.org/10.1155/2022/3851604.

MLA (9th ed.) Citation

Yan, Zijun, et al. "Norcantharidin Nanostructured Lipid Carrier (NCTD-NLC) Suppresses the Viability of Human Hepatocellular Carcinoma HepG2 Cells and Accelerates the Apoptosis." Journal of Immunology Research, vol. 2022, 2022, pp. 1-10, https://doi.org/10.1155/2022/3851604.